Efficacy And Safety Of Sabatolimab (Mbg453) In Combination With Hypomethylating Agents (Hmas) In Patients With Acute Myeloid Leukemia (Aml) And High-Risk Myelodysplastic Syndrome (Hr-Mds): Updated Results From A Phase 1b Study

Background: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. TIM-3 is expressed on immune cells as well as leukemic stem cells (LSCs) and blasts, but not normal hematopoietic stem cells, making it a promising target in AML/MDS. Sabatolimab is a potential first-in-class immunotherapeutic agent that can target TIM-3 on immune and myeloid cells. Blockade of TIM-3 by sabatolimab may restore immune function while also directly targeting LSCs and blasts.